For example, MSCs engineered to deliver IL-2 mutein dimer to tumor-infiltrating T cells exhibit capacity to reinvigorate exhausted CD8+ T cells, making it a more potent antitumor therapeutic agent [125]. This evidence concerns the gene IL2 and neoplasm.